MetiMedi Pharmaceuticals is a clinical-stage pharmaceutical company investigating
new methods of modulating cell metabolism to develop innovative therapy
for cancers and chronic inflammatory diseases.
Our Metmedi Pharmaceuticals is working on a world-class product project.
We invest heavily in internal R & D capabilities and work with outside experts
to understand the science of products and to promote innovative new product development.READ MORE
Cancer cell has unique metabolic characteristics that is quite different from a normal cell metabolism.
Cancer cell takes up large amount of glucose and converts to lactic acid continuously to produce energy
instead of TCA cycle in normal cell, which was named as Warburg effect. OMT-110 is a promising
first in class anticancer drug candidate modulating cancer cell metabolism from the suppressed glycolysis
to activation of citric acid cycle in mitochondria.READ MORE
METI-101 acts on the site where chronic inflammation is induced and shows the therapeutic effect
for chronic inflammatory diseases by correcting the metabolism of various cells induced
by chronic inflammation to the same metabolism as normal cells
and minimizing the expression of inflammatory response factors.READ MORE